Provided herein are modified antibodies, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified antibodies described herein are modified with a peptide. The peptide binds at or near the antigen binding site of the antibody at physiological pH, thus reducing binding affinity of the antibody for a target antigen. At acidic pH, the binding interaction of the peptide at or near the antigen binding site is disrupted, thus enabling binding with a target antigen.

The present invention relates to compositions and methods for the treatment of lupus, particularly systemic lupus erythematosus. The present invention involves, amongst other things, a binding protein comprising a T cell receptor (TCR) α-chain variable (Vα or Valpha) domain and a TCR β-chain variable (Vβ or Vbeta) domain, wherein the binding protein is capable of binding to a complex of a fragment of a Smith protein and an HLA-DR15 or HLA-DR3 molecule.

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

The present invention is directed to a live-attenuated Mycobacterium tuberculosis composition comprising an isolated microorganism belonging to a M. tuberculosis MTB VAC strain having a i) PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene, wherein the open-reading frame (ORF) sequence of phoP consists of SEQ ID NO 4, and ii) the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype), wherein the open-reading frame (ORF) sequence of fadD26 consists of SEQ ID NO 2, for use in therapy in a human subject in need thereof, wherein the composition is administered to said subject via pulmonary delivery.

Disclosed are methods of administering AAV viral-based vector compositions useful in delivering a variety of nucleic acid segments and compositions comprising an agent, such as an immunosuppressive agent. Methods and compositions comprising a combination therapy are provided. The disclosed AAV vector compositions include those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed AAV -based gene therapeutic regimen for treating and/or ameliorating autoimmune disorders such as multiple sclerosis. The compositions comprising an agent may comprise a sphingosine analog, a glucococorticoid, an mTOR inhibitor, and/or a targeted biologic.

The present invention relates self-replicating RNA molecules comprising a sequence encoding nonstructural alphavirus proteins and a sequence encoding a SARS-CoV-2 protein antigen.

The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.

This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.

The present disclosure provides a method for stratifying subjects with respect to their relative risk of developing anaphylaxis upon the ingestion of a peanut allergen. The method is based on the differential allergic response of the subject in a skin prick test using an Ara h 2 hypoallergenic formulation (which substantially lacks or is devoid of Ara h 8). The present disclosure also provides a peanut hypoallergenic formulation, which can be used as a reagent during the skin prick test, as an oral immunotherapy reagent or as a food product. The present disclosure further provides a process for making the peanut hypoallergenic formulation.

Described are antigen specific and antigen non-specific means of suppressing development of Type 1 Diabetes in a mammal through administration of exosomes, microvesicles or apoptotic bodies from monocytic lineage cells that have been reprogrammed by contact with mesenchymal stem cells and/or mesenchymal stem cell conditioned media. In one embodiment, the invention provides administration of exosomes that have been generated from monocytic cells that have been loaded with tolerogenic antigens and/or epitopes. In another embodiment the invention provides administration of allogeneic myeloid derived exosomes that are loaded with tolerogenic antigens. In another embodiment the invention provides means of stimulating exosome release in vivo from allogeneic cells that have been administered to the patient in need of treatment.